Sandoz gets exclusive rights to commercialize biosimilar SB17 ustekinumab in US, Canada, EEA, Switzerland and UK Ruchika Sharma11 Sept 2023 1:30 PM ISTThe reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders...
Intas Pharma marketing authorization application for proposed biosimilar of Stelara accepted by EMA Ruchika Sharma15 July 2023 11:00 AM ISTDMB-3115 is a proposed biosimilar to Stelara which is a blockbuster drug developed by Janssen Biotech Inc. for plaque psoriasis, psoriatic arthritis,...
Aurobindo Pharma arm CuraTeQ Biologics to commercialize proposed biosimilar to Stelara Ruchika Sharma8 July 2023 12:00 PM ISTCuraTeQ intends to file this product in India and Emerging Markets as early as in 2024 and the regulated markets filing is expected to begin in 2026.
Teva, Alvotech secure US license date for AVT04, a proposed biosimilar to Stelara Ruchika Sharma13 Jun 2023 1:30 PM ISTIceland: Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and...
Ustekinumab effective long term treatment for active Psoriatic Arthritis: SUSTAIN Study data Dr Supreeth D R16 Nov 2022 8:00 PM ISTPsoriatic arthritis (PsA) is a chronic, progressive disease that places a significant burden on patients and healthcare systems. The SUSTAIN study...
Biocon Biologics collaborates with Yoshindo to commercialize bUstekinumab, bDenosumab in Japan Ruchika Sharma17 Oct 2022 2:30 PM ISTDenosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.
Janssen gets USFDA nod for psoriatic arthritis treatment STELARA for pediatric patients Ruchika Sharma4 Aug 2022 11:46 AM ISTSTELARA is administered as a subcutaneous injection dosed four times per year after two starter doses for the treatment of pediatric patients six...
Abatacept fails to prevent psoriasis relapse occuring after ustekinumab withdrawal: JAMA MD Editorial Team29 Oct 2021 9:00 AM ISTResearch on psoriasis pathogenesis has largely increased knowledge on skin biology in general. The mechanisms involved in the initiation and...
Hikma Pharma, Bio-Thera ink pact to commercialize Ustekinumab biosimilar Ruchika Sharma31 Aug 2021 12:48 PM ISTLondon: Bio-Thera Solutions, Ltd. and Hikma Pharmaceuticals PLC have recently announced that they have entered into a commercialization and license...
Intas Pharma, Meiji, Dong-A ST ink licensing agreement for biosimilar to Ustekinumab Ruchika Sharma24 July 2021 9:00 AM ISTAhmedabad: Intas Pharmaceuticals Ltd has announced that the company has entered into an exclusive license agreement with Meiji and Dong-A Socio...
JAMA study throws light on effectiveness of biologic therapies in psoriasis Medha Baranwal17 Jan 2021 7:00 PM ISTUK: A recent study revealed that there is a gap between the efficacy of biologic therapies in an idealized trial setting and effectiveness of biologic...
FDA approves ustekinumab for plaque psoriasis in kids Dr. Kamal Kant Kohli31 July 2020 8:30 PM ISTHORSHAM -- The U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA (ustekinumab) as a treatment for pediatric...
